Table 5

Cyclin D1 and E-cadherin mRNA in ACF cryptsa

Treatment groupCyclin D1E-cadherin
AOM817 ± 167b91 ± 55
AOM+ UDCA75 ± 20c170 ± 75
AOM+ F6-D378 ± 34c165 ± 72
  • a Cyclin D1 and E-cadherin mRNA levels in the indicated groups assessed by real-time PCR as described in the “Materials and Methods” (n = 6 animals in each group, with 4 ACF biopsies from each carcinogen-treated rat and 4 normal biopsies from controls). Data are expressed as % cyclin D1 or E-cadherin mRNA in normal crypts from saline-treated rats (means ± SE). Cyclin D1 and E-cadherin mRNA were comparable among the saline-treated unsupplemented group and UDCA and F6-D3-supplemented groups.

  • b P < 0.05, compared with control crypts.

  • c P < 0.05, compared with ACF crypts in the AOM-alone group. Samples were normalized to β-actin mRNA expression.